Milestone Pharmaceuticals ( (MIST) ) just unveiled an announcement.
On February 25, 2025, Milestone Pharmaceuticals announced its preparation for the potential launch of CARDAMYST, a nasal spray containing etripamil, pending FDA approval. The company anticipates a significant impact on its operations with the expected approval and commercial launch in mid-2025, which could extend its patent estate to 2042 and provide a $75 million payment upon approval. This development is seen as transformative for Milestone, potentially reducing healthcare costs and empowering patients by providing a new therapeutic option.
More about Milestone Pharmaceuticals
Milestone Pharmaceuticals is a biopharmaceutical company focused on developing therapies for cardiovascular diseases. Their primary product is the etripamil nasal spray, intended for patients with paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid rate (AFib-RVR).
YTD Price Performance: -12.90%
Average Trading Volume: 664,301
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $100.8M
For detailed information about MIST stock, go to TipRanks’ Stock Analysis page.